China Pharma Holdings (CPHI) Change in Accured Expenses (2010 - 2026)
China Pharma Holdings (CPHI) posted Change in Accured Expenses of -$14258.0 for Q1 2026, down 103.29% on a QoQ basis from $432777.0 in Q4 2025, and up 81.91% year-over-year from -$7838.0 in Q1 2025.
China Pharma Holdings (CPHI) Change in Accured Expenses (2010 - 2026) Analysis & Trends
China Pharma Holdings' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$14258.0 for Q1 2026.
- Quarterly Change in Accured Expenses rose 81.91% year-over-year to -$14258.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $530304.0 (down 24.28% YoY) and the FY2025 annual result came in at $465753.0, up 8.01% from the prior year.
- Change in Accured Expenses was -$14258.0 for Q1 2026 at China Pharma Holdings, down from $432777.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $804339.0 in Q4 2022 and bottomed at -$450887.0 in Q1 2023.
- A 5-year average of $107804.6 and a median of $25734.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 579.2% — and 2023, when it jumped 940.44%.
- China Pharma Holdings' Change in Accured Expenses stood at $804339.0 in 2022, then tumbled by 47.67% to $420886.0 in 2023, then jumped by 73.24% to $729131.0 in 2024, then slumped by 40.64% to $432777.0 in 2025, then tumbled by 103.29% to -$14258.0 in 2026.
- Business Quant data shows CPHI's Change in Accured Expenses at -$14258.0 in Q1 2026, $432777.0 in Q4 2025, and -$68702.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -14,258.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,258.00 |
| Mar 31, 2026 | -14,258.00 |
| Dec 31, 2025 | 432,777.00 |
| Dec 31, 2025 | 432,777.00 |
| Sep 30, 2025 | -68,702.00 |
| Sep 30, 2025 | -68,702.00 |
| Jun 30, 2025 | 180,487.00 |
| Jun 30, 2025 | 180,487.00 |
| Mar 31, 2025 | -78,809.00 |
| Mar 31, 2025 | -78,809.00 |
| Dec 31, 2024 | 729,131.00 |
| Dec 31, 2024 | 729,131.00 |
| Sep 30, 2024 | -56,482.00 |
| Sep 30, 2024 | -56,482.00 |
| Jun 30, 2024 | 106,548.00 |
| Jun 30, 2024 | 106,548.00 |
| Mar 31, 2024 | -347,982.00 |
| Mar 31, 2024 | -347,982.00 |
| Dec 31, 2023 | 420,886.00 |
| Dec 31, 2023 | 420,886.00 |